News Otsuka grows in neuroplastogens with $1.225bn Transcend buy Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.
R&D Neuroplastogens: A novel approach to treat neurological dise... In the US alone, one in five adults experiences a form of mental illness each year. New medicines are urgently needed, as current therapies fail to work in up to a third of patients.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.